Emicizumab treatment in hemophilia A with inhibitors. A case report and cost-minimization analysis of a non-responder to conventional treatment patient

被引：0
|
作者：
Martinez Garcia, M. F. [1 ]
Fernandez Caballero, M. [1 ]
Juarez Gimenez, J. C. [2 ]
Serna Pareja, A. [1 ]
Cerda Sabater, M. [1 ]
Johansson, E. [1 ]
Alvarez Martinez, E. [1 ]
Fernandez Sarmiento, C. [1 ]
Bosch Albareda, F. [1 ]
Santamaria Ortiz, A. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Hemophilia Unit, Hematol Dept, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Hemophilia Unit, Dept Hosp Pharm, Barcelona, Spain
来源：
HAEMOPHILIA | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P191
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [41] Medical versus surgical treatment of first trimester spontaneous abortion: A cost-minimization analysis
    Cubo Nava, Ana
    Soto Pino, Zandra M.
    Haro Perez, Ana M.
    Hernandez Hernandez, M. Estrella
    Doyague Sanchez, M. Jose
    Sayagues Manzano, Jose M.
    PLOS ONE, 2019, 14 (01):
  • [42] COST-MINIMIZATION ANALYSIS OF VISCOSUPPLEMENTATION TREATMENT OSTEOARTHRITIS OF KNEE IN BRAZIL'S PRIVATE SECTOR
    Bueno, R. L. P.
    Stefani, S.
    VALUE IN HEALTH, 2009, 12 (07) : A523 - A524
  • [43] COST-MINIMIZATION ANALYSIS FOR SUBCUTANEOUS DARATUMUMAB IN THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA IN QATAR
    Hamad, A.
    Elazzazy, S.
    Taha, R.
    Emara, S.
    Elsisi, G.
    VALUE IN HEALTH, 2024, 27 (12) : S90 - S90
  • [44] Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report
    Guillaume, Louise
    van Dievoet, Marie-Astrid
    Lambert, Catherine
    Hermans, Cedric
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [45] Cost-minimization analysis of voriconazole and caspofungin for the treatment of invasive candida and aspergillosis infections in Spain
    Domínguez-Gil, HA
    Herranz, MI
    Garcia, VM
    Rejas, J
    VALUE IN HEALTH, 2004, 7 (06) : 764 - 764
  • [46] COST-MINIMIZATION ANALYSIS OF BIOLOGICAL DRUGS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM A BRAZILIAN PERSPECTIVE
    Lopes, N.
    Suzuki, C.
    Tozato, C.
    VALUE IN HEALTH, 2018, 21 : S198 - S198
  • [47] Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors
    Sun, Shawn X.
    Wu, Yanyu
    McDermott, Michael
    van Keep, Marjolijn
    BLOOD, 2019, 134
  • [48] COST-MINIMIZATION ANALYSIS OF BIOLOGICAL DRUGS IN THE TREATMENT OF PSORIATIC ARTHRITIS FROM A BRAZILIAN PERSPECTIVE
    Lopes, N.
    Suzuki, C.
    Tozato, C.
    VALUE IN HEALTH, 2018, 21 : S198 - S198
  • [49] A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections
    Turco, Neil J.
    Kane-Gill, Sandra L.
    Hernandez, Inmaculada
    Oleksiuk, Louise-Marie
    D'Amico, Frank
    Pickering, Aaron J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 319 - 325
  • [50] COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES
    Li, N.
    Bullement, A.
    McMordie, S.
    Hatswell, A. J.
    Wilson, K.
    VALUE IN HEALTH, 2019, 22 : S389 - S389
12345